Literature DB >> 25689954

Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K.

Rupert Courtnay1, Darleen C Ngo, Neha Malik, Katherine Ververis, Stephanie M Tortorella, Tom C Karagiannis.   

Abstract

Cancer cells have been shown to have altered metabolism when compared to normal non-malignant cells. The Warburg effect describes a phenomenon in which cancer cells preferentially metabolize glucose by glycolysis, producing lactate as an end product, despite being the presence of oxygen. The phenomenon was first described by Otto Warburg in the 1920s, and has resurfaced as a controversial theory, with both supportive and opposing arguments. The biochemical aspects of the Warburg effect outline a strong explanation for the cause of cancer cell proliferation, by providing the biological requirements for a cell to grow. Studies have shown that pathways such as phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) as well as hypoxia inducible factor-1 (HIF-1) are central regulators of glycolysis, cancer metabolism and cancer cell proliferation. Studies have shown that PI3K signaling pathways have a role in many cellular processes such as metabolism, inflammation, cell survival, motility and cancer progression. Herein, the cellular aspects of the PI3K pathway are described, as well as the influence HIF has on cancer cell metabolism. HIF-1 activation has been related to angiogenesis, erythropoiesis and modulation of key enzymes involved in aerobic glycolysis, thereby modulating key processes required for the Warburg effect. In this review we discuss the molecular aspects of the Warburg effect with a particular emphasis on the role of the HIF-1 and the PI3K pathway.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25689954     DOI: 10.1007/s11033-015-3858-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  53 in total

Review 1.  Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning.

Authors:  Gregg L Semenza
Journal:  Biochim Biophys Acta       Date:  2010-08-21

Review 2.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

3.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

4.  HIF-1α downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation.

Authors:  M He; Q-Y Wang; Q-Q Yin; J Tang; Y Lu; C-X Zhou; C-W Duan; D-L Hong; T Tanaka; G-Q Chen; Q Zhao
Journal:  Cell Death Differ       Date:  2012-10-12       Impact factor: 15.828

5.  Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain.

Authors:  M Bergeron; J M Gidday; A Y Yu; G L Semenza; D M Ferriero; F R Sharp
Journal:  Ann Neurol       Date:  2000-09       Impact factor: 10.422

6.  Hypoxia regulation of facilitated glucose transporter-1 and glucose transporter-3 in mouse chondrocytes mediated by HIF-1alpha.

Authors:  Bu-Fang Ren; Lian-Fu Deng; Jun Wang; Ya-Ping Zhu; Li Wei; Qi Zhou
Journal:  Joint Bone Spine       Date:  2007-08-31       Impact factor: 4.929

Review 7.  Rethinking the Warburg effect with Myc micromanaging glutamine metabolism.

Authors:  Chi V Dang
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

8.  In vitro and in vivo study of phloretin-induced apoptosis in human liver cancer cells involving inhibition of type II glucose transporter.

Authors:  Chih-Hsiung Wu; Yuan-Soon Ho; Chia-Yi Tsai; Ying-Jan Wang; How Tseng; Po-Li Wei; Chia-Hwa Lee; Ren-Shyan Liu; Shyr-Yi Lin
Journal:  Int J Cancer       Date:  2009-05-01       Impact factor: 7.396

9.  Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells.

Authors:  Weibo Luo; Gregg L Semenza
Journal:  Oncotarget       Date:  2011-07

Review 10.  Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer.

Authors:  E D Michelakis; L Webster; J R Mackey
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

View more
  151 in total

1.  Correlation and expression analysis of hypoxia-inducible factor 1α, glucose transporter 1 and lactate dehydrogenase 5 in human gastric cancer.

Authors:  Lang-Song Hao; Qi Liu; Chuan Tian; Dong-Xing Zhang; Bo Wang; Dong-Xu Zhou; Zhao-Peng Li; Zhi-Xiang Yuan
Journal:  Oncol Lett       Date:  2019-06-07       Impact factor: 2.967

2.  A cardiac myocyte-restricted Lin28/let-7 regulatory axis promotes hypoxia-mediated apoptosis by inducing the AKT signaling suppressor PIK3IP1.

Authors:  Shaurya Joshi; Jianqin Wei; Nanette H Bishopric
Journal:  Biochim Biophys Acta       Date:  2015-12-02

3.  Perspective: Do Fasting, Caloric Restriction, and Diets Increase Sensitivity to Radiotherapy? A Literature Review.

Authors:  Philippe Icard; Luc Ollivier; Patricia Forgez; Joelle Otz; Marco Alifano; Ludovic Fournel; Mauro Loi; Juliette Thariat
Journal:  Adv Nutr       Date:  2020-09-01       Impact factor: 8.701

Review 4.  Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example.

Authors:  Haitham A Badr; Dina M M AlSadek; Motawa E El-Houseini; Christopher T Saeui; Mohit P Mathew; Kevin J Yarema; Hafiz Ahmed
Journal:  Biomaterials       Date:  2016-11-25       Impact factor: 12.479

5.  The TCL1 function revisited focusing on metabolic requirements of stemness.

Authors:  Maria Teresa Fiorenza; Alessandro Rava
Journal:  Cell Cycle       Date:  2019-09-29       Impact factor: 4.534

6.  New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation.

Authors:  Justin L Tan; Feng Li; Joanna Z Yeo; Kol Jia Yong; Mahmoud A Bassal; Guo Hao Ng; May Yin Lee; Chung Yan Leong; Hong Kee Tan; Chan-Shuo Wu; Bee Hui Liu; Tim H Chan; Zi Hui Tan; Yun Shen Chan; Siyu Wang; Zhi Han Lim; Tan Boon Toh; Lissa Hooi; Kia Ngee Low; Siming Ma; Nikki R Kong; Alicia J Stein; Yue Wu; Matan T Thangavelu; Atsushi Suzuki; Giridharan Periyasamy; John M Asara; Yock Young Dan; Glenn K Bonney; Edward K Chow; Guo-Dong Lu; Huck Hui Ng; Yoganathan Kanagasundaram; Siew Bee Ng; Wai Leong Tam; Daniel G Tenen; Li Chai
Journal:  Gastroenterology       Date:  2019-08-22       Impact factor: 22.682

7.  Shikonin, vitamin K3 and vitamin K5 inhibit multiple glycolytic enzymes in MCF-7 cells.

Authors:  Jing Chen; Xun Hu; Jingjie Cui
Journal:  Oncol Lett       Date:  2018-03-13       Impact factor: 2.967

8.  Silencing LDHA inhibits proliferation, induces apoptosis and increases chemosensitivity to temozolomide in glioma cells.

Authors:  Hui Di; Xinting Zhang; Yi Guo; Yanfang Shi; Chuan Fang; Yu Yuan; Jiwei Wang; Chao Shang; Wenzhe Guo; Chunhui Li
Journal:  Oncol Lett       Date:  2018-02-02       Impact factor: 2.967

9.  Expression of MMIF, HIF-1α and VEGF in Serum and Endometrial Tissues of Patients with Endometriosis.

Authors:  Fan Zhang; Xiao-Ling Liu; Wan Wang; Hong-Ling Dong; Yu-Fang Xia; Li-Ping Ruan; Li-Ping Liu
Journal:  Curr Med Sci       Date:  2018-06-22

10.  Metabolic Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes by Inhibition of HIF1α and LDHA.

Authors:  Dongjian Hu; Annet Linders; Abir Yamak; Cláudia Correia; Jan David Kijlstra; Arman Garakani; Ling Xiao; David J Milan; Peter van der Meer; Margarida Serra; Paula M Alves; Ibrahim J Domian
Journal:  Circ Res       Date:  2018-10-12       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.